Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 121Lymphoma, Mantle-Cell 20Leukemia 14Lymphoma, Non-Hodgkin 13Lymphoma, Follicular 11Neoplasms 10Leukemia, B-Cell 10Waldenstrom Macroglobulinemia 9Recurrence 9Lymphoma, B-Cell 9Lymphoma, Large B-Cell, Diffuse 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Lymphoid 8Lymphoma 7Hematologic Neoplasms 7Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Bronchiolitis Obliterans Syndrome 5Leukemia, Prolymphocytic 4Burkitt Lymphoma 4Leukemia, Hairy Cell 3Chromosome 17 deletion 3Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Prolymphocytic, B-Cell 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Immunoproliferative Disorders 2Immune System Diseases 2

Interventions

tanespimycin 1ibrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multi-centric Castleman's Disease × ibrutinib × Other hematologic neoplasm × Clear all
NCT02109224 2015-08-20

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

National Cancer Institute (NCI)

Phase 1 Terminated
72 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multi-centric Castleman's Disease, Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, HIV Infections, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡